Table 2.
Cancer type | miRNAs | Specimen | Reference | Use |
---|---|---|---|---|
Acute Myeloid Leukemia | miR-155-3p, miR-181-5p | Serum | 143 | D, P |
miR-150, miR-342 | Plasma | 144 | D, P | |
miR-10-5p | Serum | 145 | D, P | |
miR-210 | Serum | 146 | P | |
miR-155 | Blood | 147 | P | |
miR-10b | Exosomes | 148 | D, P | |
miR-203 | Serum | 149 | D, P | |
Acute lymphoblastic Leukemia | miR-511, miR- 222, miR-34a, miR-199a-3p, miR-223, miR-221, | Plasma | 152 | D |
miR-26a | ||||
miR-155, miR-126 | Plasma | 153 | P | |
miR-125b-1, miR-203 | Serum | 154 | D | |
Chronic Lymphocytic Leukemia | miR-155 | Plasma | 156 | P, T |
miR-155, miR-150, miR-29a, miR-29b and miR-29c | Exosomes | 157 | D | |
miR-150 | Serum | 158 | P | |
miR-29b | 159 | D, P | ||
Non-Hodgkin Lymphoma | miR-155, miR-210, miR-21 | Serum | 10 | D, P |
miR-15a, miR-16-1, miR-29c, miR-155, miR-34a | Serum | 162 | D | |
miR-130a, miR-125b | Serum | 163 | P, T | |
Multiple Myeloma | miR-451, miR-638, miR-720, miR-1246, miR-1308, miR-1915 | Serum | 164 | D |
miR-92a | Plasma | 165 | D, P, T | |
miR-148a, miR-181a, miR-20a, miR-221, miR-625, miR-99b | Blood | 166 | D, P | |
miR-142-5p, miR-660, miR-29a | Serum | 167 | D | |
miR-130a, miR-34a, let-7d, miR-744, let-7e | Serum | 168 | D, P | |
miR-92a, miR-30a, miR-451, miR-720, miR-16, miR-25 | Serum | 169 | D, P | |
miR-1207-5p, miR-3656, miR-630, miR-451, miR-92a, | Plasma | 170 | D | |
miR-22, miR-223, miR-19b, miR-720, miR-16, miR-20a | ||||
miR-483-5p | D, P | |||
miR-214, miR-135b | Serum | 171 | D, P | |
miR-19a | Serum | 172 | P | |
miR-19a,miR-26a-5p, miR-29c-3p, miR-30b-5p, miR-30c-5p, | Serum | 173 | T | |
miR-331-3p | ||||
miR-16, miR-17, miR-20a, miR-660, miR-19b, miR-331 | Serum | 174 | D, P, T | |
miR-130a | Serum | 175 | D |
D: diagnosis; P: prognosis; T: response to therapy